▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Imv (NASDAQ: IMV)

Some price data may be temporarily unavailable.

Imv Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
IMV	0.00%	-100.00%	-96.77%	-100%
S&P	+10.93%	+85.96%	+13.20%	+355%

Imv Company Info

IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.

News & Analysis

Featured Article

Why Several Coronavirus Vaccine Stocks Not Named Moderna Fell Today

Good news for Moderna was bad news for several of its rivals.

Keith Speights | Jul 15, 2020

Valuation

Earnings Transcripts

IMV Inc. (IMV) Q2 2021 Earnings Call Transcript

IMV earnings call for the period ending June 30, 2021.

Motley Fool Transcribing | Aug 11, 2021

IMV Inc. (IMV) Q1 2021 Earnings Call Transcript

IMV earnings call for the period ending March 31, 2021.

Motley Fool Transcribing | May 12, 2021

IMV Inc. (IMV) Q4 2020 Earnings Call Transcript

IMV earnings call for the period ending December 31, 2020.

Motley Fool Transcribing | Mar 17, 2021

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services